RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

被引：0
|
作者：
Jiajun Wang
Sihong Zhang
Ying Wang
Yanjun Zhu
Xianglai Xu
Jianming Guo
机构：
[1] Fudan University,Department of Urology, Zhongshan Hospital
[2] Fudan University,Department of Critical Care Medicine, Zhongshan Hospital
来源：
BMC Urology | / 24卷
关键词：
Renal cell carcinoma; Runt-related transcription factor 3; Immune checkpoint inhibition plus tyrosine kinase inhibition; Immune evasion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
    Gu, L.
    Liang, Q.
    Zhang, X.
    Wang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1507 - S1507
  • [22] Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
    Adashek, Jacob J.
    Salgia, Meghan
    Dizman, Nazli
    Kessler, Jonathan
    Pal, Sumanta K.
    CASE REPORTS IN ONCOLOGY, 2018, 11 (02): : 276 - 280
  • [23] Clinical outcomes of tyrosine kinase inhibitors immediately after immune checkpoint inhibitors in renal cell carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyousuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Uemura, Motohide
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2022, 33 : S497 - S497
  • [24] AI-driven multifaceted predictive biomarkers of response to tyrosine kinase inhibition and immune checkpoint blockade in clear cell renal cell carcinoma.
    Miheecheva, Natalia
    Lyu, Yang
    Ramachandran, Akshaya
    Stupichev, Danil
    Bagaev, Alexander
    Postovalova, Ekaterina
    Nomie, Krystle
    Frenkel, Felix
    Fowler, Nathan
    Ataullakhanov, Ravshan
    Hsieh, James J.
    CANCER RESEARCH, 2021, 81 (13)
  • [25] Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)
    Harshman, Lauren C.
    Yu, R. James
    Allen, Genevera I.
    Srinivas, Sandy
    Gill, Harcharan S.
    Chung, Benjamin I.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (03) : 379 - 385
  • [26] Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma
    Stuhler, Viktoria
    Rausch, Steffen
    Maas, Jan Moritz
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (09) : 1215 - 1226
  • [27] Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma
    Lyu, Chen
    Li, Wenyue
    Liu, Songcai
    Gao, Shuang
    Zhang, Hong
    Hao, Linlin
    Yu, Hao
    Wei, Wenzhen
    Song, Jie
    Yang, Yaoyao
    Wang, Chunmeng
    Zhang, Zhimin
    Wang, Nan
    FUTURE ONCOLOGY, 2018, 14 (21) : 2207 - 2221
  • [28] Biomarkers in renal cell carcinoma: Towards a more selective immune checkpoint inhibition
    Sarkis, J.
    Assaf, J.
    Alkassis, M.
    TRANSLATIONAL ONCOLOGY, 2021, 14 (06):
  • [29] Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
    Jammihal, Tejas
    Saliby, Renee Maria
    Labaki, Chris
    Soulati, Hanna
    Gallegos, Juan
    Peris, Arnau
    Mccurry, Dustin
    Yu, Chunlei
    Shah, Valisha
    Poduval, Deepak
    El Zarif, Talal
    El Ahmar, Nourhan
    Laimon, Yasmin Nabil
    Eid, Marc
    Sheshdeh, Aseman Bagheri
    Krajewski, Katherine M.
    Buttner, Florian A.
    Schwab, Matthias
    Heng, Daniel
    Casellas, Rafael C.
    Rai, Kunal
    Zacharias Millward, Niki M.
    Msaouel, Pavlos
    Karam, Jose
    Signoretti, Sabina
    Van Allen, Eliezer
    Choueiri, Toni K.
    Braun, David A.
    Shukla, Sachet A.
    NATURE CANCER, 2025, 6 (02) : 372 - 384
  • [30] Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
    Ugurel, Selma
    Roehmel, Joachim
    Ascierto, Paolo A.
    Becker, Jurgen C.
    Flaherty, Keith T.
    Grob, Jean J.
    Hauschild, Axel
    Larkin, James
    Livingstone, Elisabeth
    Long, Georgina, V
    Lorigan, Paul
    McArthur, Grant A.
    Ribas, Antoni
    Robert, Caroline
    Zimmer, Lisa
    Schadendorf, Dirk
    Garbe, Claus
    EUROPEAN JOURNAL OF CANCER, 2020, 130 : 126 - 138
12345